Biogen Inc (BIIB)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$176.00
Buy
$178.80
$-6.44 (-3.50%)
Prices updated at 03 Apr 2026, 00:49 EDT
| Prices minimum 15 mins delay
Prices in USD
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Ms. Caroline D. Dorsa
CEO
Mr. Christopher A. Viehbacher
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
7,500
Head office
225 Binney Street
Cambridge
United States
02142
Key personnel
Owner name | Salary |
|---|---|
Ms. Caroline D. Dorsa Chairman of the Board | 0.23m |
Ms. Susan H. Alexander Executive Vice President and Chief Legal Officer | 0.95m |
Dr. Maria C. Freire, PhD Independent Director | 0.14m |
Dr. Eric K. Rowinsky,M.D. Independent Director | 0.16m |
Mr. William A. Hawkins, III Independent Director | 0.17m |
Dr. Stephen A. Sherwin, M.D. Independent Director | 0.14m |
Mr. Christopher A. Viehbacher Director, President and Chief Executive Officer | 1.60m |
Dr. Ginger Gregory, PhD Executive Vice President and Chief Human Resources Officer | - |
Professor Menelas Pangalos, PhD Independent Director | - |
Ms. Robin C. Kramer Executive Vice President and Chief Financial Officer | - |
Dr. Priya Singhal, M.D.,M.P.H. Executive Vice President and Head of Development | 0.82m |
Mr. Jesus B. Mantas Independent Director | 0.17m |
Mr. Monish D. Patolawala Independent Director | 0.14m |
Dr. Jane Grogan, PhD Executive Vice President, Head of Research | - |
Mr. Rachid Izzar Executive Vice President, Global Product Strategy and Commercialization | - |
Ms. Nicole Murphy Executive Vice President, Pharmaceutical Operations and Technology | 0.76m |
Mr. Adam Keeney, PhD Executive Vice President and Head of Corporate Development | - |
Ms. Susan K. Langer Independent Director | 0.13m |
Dr. Lloyd B. Minor, M.D. Independent Director | 0.03m |
Mr. Sean Godbout Vice President, Chief Accounting Officer and Global Corporate Controller | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard Group Inc | 17,447,092 |
| BlackRock Inc | 14,763,952 |
| PRIMECAP Management Company | 14,757,997 |
| Fidelity Management & Research Company LLC | 9,964,406 |
| FMR Inc | 9,425,863 |
Director dealings
Date | Action |
|---|---|
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 01 Dec 2025 | - |
| 31 Oct 2025 | - |
| 31 Oct 2025 | - |
| 31 Oct 2025 | - |
| 02 Oct 2025 | - |
| 02 Oct 2025 | - |
| 02 Oct 2025 | - |
| 29 Aug 2025 | - |
| 29 Aug 2025 | - |
| 02 Sep 2025 | - |
| 29 Aug 2025 | - |
| 08 Jul 2025 | - |
| 17 Jun 2025 | - |
| 17 Jun 2025 | - |
| 17 Jun 2025 | - |
| 17 Jun 2025 | - |
| 17 Jun 2025 | - |
| 17 Jun 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
